Multivariate analysis of predictive factors for progression-free survival (PFS) in EGFR mutant patients treated with epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs)
| Factors | Patients n | Median PFS months | Univariate analysis p-value | Multivariate analysis | |
| Hazard ratio (95% CI) | p-value | ||||
| Age years | 0.033 | ||||
| ≤50 | 81 | 7.3 | 1 | ||
| 51–60 | 117 | 8.7 | 0.80 (0.59–1.08) | 0.144 | |
| 61–70 | 134 | 9.6 | 0.66 (0.49–0.90) | 0.009 | |
| 71–80 | 128 | 10.1 | 0.69 (0.50–0.93) | 0.016 | |
| >80 | 64 | 8.8 | 0.54 (0.37–0.80) | 0.002 | |
| Sex | 0.247 | ||||
| Female | 308 | 9.1 | 1 | ||
| Male | 216 | 8.7 | 1.09 (0.88–1.36) | 0.428 | |
| Smoking history | 0.015 | ||||
| Never-smoker | 419 | 9.1 | 1 | ||
| Ex-smoker | 52 | 9.4 | 0.94 (0.66–1.32) | 0.705 | |
| Current smoker | 53 | 6.9 | 1.40 (1.00–1.96) | 0.052 | |
| ECOG PS | 0.001 | ||||
| 0–1 | 449 | 9.4 | 1 | ||
| 2–4 | 75 | 6.0 | 1.86 (1.38–2.50) | <0.001 | |
| EGFR mutation | 0.002 | ||||
| Uncommon | 63 | 3.6 | 1 | ||
| Del-19 | 233 | 9.7 | 0.63 (0.46–0.86) | 0.003 | |
| L858R | 228 | 9.1 | 0.72 (0.53–0.99) | 0.041 | |
| TKI sequence | 0.487 | ||||
| First-line | 339 | 9.0 | 1 | ||
| Second-line | 117 | 8.5 | 0.89 (0.70–1.13) | 0.336 | |
| Third-line or greater | 68 | 9.0 | 0.94 (0.71–1.24) | 0.643 | |
ECOG PS: Eastern Cooperative Oncology Group performance status.